Hypothesis\nChronic low‑dose NSAID exposure accelerates biological aging by simultaneously suppressing prostaglandin‑mediated hormetic signaling and depleting gut microbes that produce indole‑3‑propionic acid (IPA).\n\n## Mechanistic Rationale\n1. NSAIDs inhibit cyclooxygenase‑1/2, lowering prostaglandin E2 (PGE2) levels. PGE2 acting on EP2/EP4 receptors raises cAMP, which can activate CREB‑driven expression of tryptophanase in certain Clostridia, boosting IPA synthesis. Reduced PGE2 therefore diminishes microbial IPA production.\n2. IPA is a potent antioxidant and Nrf2 activator that preserves intestinal barrier integrity and suppresses systemic inflammation. Lower IPA leads to increased gut permeability, endotoxin translocation, and chronic low‑grade inflammation—known drivers of epigenetic aging.\n3. Beyond the microbiome, PGE2‑EP signaling in epithelial cells triggers mild oxidative stress that activates Nrf2 and HSP70 pathways, a hormetic loop that enhances cellular repair. Chronic NSAID blunts this loop, removing a protective signal.\n\n## Testable Predictions\n- In a 12‑month, double‑blind RCT, participants receiving low‑dose ibuprofen (200 mg daily) will show:\n * A ≥15 % reduction in fecal IPA concentration relative to placebo (measured by LC‑MS/MS).\n * A corresponding rise in plasma zonulin or LPS‑binding protein, indicating heightened gut permeability.\n * An acceleration of epigenetic age (GrimAge) of ~0.5 years compared with controls, after adjusting for baseline age, BMI, and medication use.\n- Conversely, supplementation with IPA (10 mg/kg/day) in the NSAID arm will rescue barrier function and blunt epigenetic age acceleration.\n\n## Potential Confounders and Controls\n- Exclude participants using antibiotics, probiotics, or other NSAIDs.\n- Stratify by baseline IPA producers (quantified via 16S sequencing targeting Clostridium sporogenes and related taxa).\n- Monitor analgesic use via pill counts and plasma drug levels.\n- Record pain scores to ensure any observed effects are not secondary to altered pain perception.\n\n## Expected Outcomes and Implications\nIt's expected that, if the hypothesis holds, low‑dose NSAID users will exhibit a measurable shift toward older epigenetic profiles despite reporting lower pain scores, revealing a hidden cost of analgesic‑induced signaling quieting. This would motivate re‑evaluation of OTC NSAID guidelines, suggest microbiome‑targeted interventions (e.g., IPA‑producing probiotics or prebiotics) for chronic pain patients, and reposition IPA as a biomarker of analgesic‑related aging risk.\n\nIf the IPA decrease and epigenetic acceleration are not observed, the hypothesis won't be supported.
